- Home
- FIVN vs TVTX Comparison
FIVN vs TVTX Comparison
Compare FIVN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- TVTX
- Stock Information
- Founded
- FIVN 2001
- TVTX 2008
- Country
- FIVN United States
- TVTX United States
- Employees
- FIVN 3073
- TVTX 385
- Industry
- FIVN EDP Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- FIVN Technology
- TVTX Health Care
- Exchange
- FIVN Nasdaq
- TVTX Nasdaq
- Market Cap
- FIVN 1.7B
- TVTX 2.3B
- IPO Year
- FIVN 2014
- TVTX N/A
- Fundamental
- Price
- FIVN $21.84
- TVTX $26.30
- Analyst Decision
- FIVN Buy
- TVTX Strong Buy
- Analyst Count
- FIVN 19
- TVTX 16
- Target Price
- FIVN $37.47
- TVTX $35.20
- AVG Volume (30 Days)
- FIVN 1.9M
- TVTX 1.9M
- Earning Date
- FIVN 11-06-2025
- TVTX 10-30-2025
- Dividend Yield
- FIVN N/A
- TVTX N/A
- EPS Growth
- FIVN N/A
- TVTX N/A
- EPS
- FIVN 0.11
- TVTX N/A
- Revenue
- FIVN $1,105,816,000.00
- TVTX $333,865,000.00
- Revenue This Year
- FIVN $12.39
- TVTX $84.12
- Revenue Next Year
- FIVN $9.56
- TVTX $40.82
- P/E Ratio
- FIVN $204.73
- TVTX N/A
- Revenue Growth
- FIVN 14.21
- TVTX 87.94
- 52 Week Low
- FIVN $20.48
- TVTX $12.91
- 52 Week High
- FIVN $49.90
- TVTX $28.69
- Technical
- Relative Strength Index (RSI)
- FIVN 37.54
- TVTX 65.48
- Support Level
- FIVN $20.49
- TVTX $25.09
- Resistance Level
- FIVN $25.68
- TVTX $27.21
- Average True Range (ATR)
- FIVN 1.03
- TVTX 1.30
- MACD
- FIVN -0.17
- TVTX -0.12
- Stochastic Oscillator
- FIVN 26.66
- TVTX 82.33
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.